The Pharmaceutical Research Center (PRC) (previously named Investigational Drug Services/IDS) ensures the safe and ethical provision of investigational/study drugs to research subjects enrolled in clinical drug trials within the UWCCC. It ensures that drug research protocols proceed optimally through the University of Wisconsin Hospital and Clinics'(UWHC) medication use system and in accordance with all federal, state, institutional and sponsor regulations: The services are continually refined and expanded to meet the evolving needs of the UWCCC clinical research. While the PRC program at UW/UWHC supports all investigators conducting clinical drug research, its relationship with the UWCCC is unique in its level of commitment, the breadth and depth of services provided, and expertise in handling biohazardous and gene therapy products. The PRC provides detailed protocol review and feasibility assessment within the confines of an academic medical center. It ensures full compliance with federal, state, sponsor and institutional requirements through activities such as: establishment of drug handlihg/distribution/preparation/destruction procedures;creation of investigational drug monographs for health care providers;education of health care staff regarding protocol procedures;creation of preprinted physician orders and prescriptions;drug inventory management and accountability;drug preparation and/or oversight;quality assurance audits;and protocol amendment management. It operates satellite pharmacy locations, optimizing ability to extend clinical research into the community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-38
Application #
8250412
Study Section
Subcommittee G - Education (NCI)
Project Start
2011-04-01
Project End
2013-03-31
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
38
Fiscal Year
2011
Total Cost
$84,778
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164
Jadvar, Hossein; Chen, Xiaoyuan; Cai, Weibo et al. (2018) Radiotheranostics in Cancer Diagnosis and Management. Radiology 286:388-400
Denu, Ryan A; Shabbir, Maria; Nihal, Minakshi et al. (2018) Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Mol Cancer Res 16:517-527
England, Christopher G; Jiang, Dawei; Ehlerding, Emily B et al. (2018) 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging 45:110-120
Ong, Irene M; Gonzalez, Jose G; McIlwain, Sean J et al. (2018) Gut microbiome populations are associated with structure-specific changes in white matter architecture. Transl Psychiatry 8:6
Trentham-Dietz, Amy; Ergun, Mehmet Ali; Alagoz, Oguzhan et al. (2018) Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening. Breast Cancer Res Treat 168:229-239
Weiss, Jennifer M; Pandhi, Nancy; Kraft, Sally et al. (2018) Primary care colorectal cancer screening correlates with breast cancer screening: implications for colorectal cancer screening improvement interventions. Clin Transl Gastroenterol 9:148
Bruce, Jordan G; Tucholka, Jennifer L; Steffens, Nicole M et al. (2018) Feasibility of Providing Web-Based Information to Breast Cancer Patients Prior to a Surgical Consult. J Cancer Educ 33:1069-1074
Huynh, Mailee; Pak, Chorom; Markovina, Stephanie et al. (2018) Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-?B activity and increases drug resistance in multiple myeloma. J Biol Chem 293:2452-2465
Wu, Yirong; Fan, Jun; Peissig, Peggy et al. (2018) Quantifying predictive capability of electronic health records for the most harmful breast cancer. Proc SPIE Int Soc Opt Eng 10577:

Showing the most recent 10 out of 1528 publications